X

Trial Profile

A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1390 (Primary) ; Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms CONCORDE

Most Recent Events

04 Jun 2024 Trial in progress poster presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
28 Feb 2024 Results ( As of 01/11/23, n= 20 )presented at the ESMO Targeted Anticancer Therapies Congress 2024
23 Feb 2024 Treatments section is updated to add Ceralasertib oral tablet and Durvalumab IV infusion into the study drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com